CA2425368C - New sulphoxybenzamides - Google Patents
New sulphoxybenzamides Download PDFInfo
- Publication number
- CA2425368C CA2425368C CA002425368A CA2425368A CA2425368C CA 2425368 C CA2425368 C CA 2425368C CA 002425368 A CA002425368 A CA 002425368A CA 2425368 A CA2425368 A CA 2425368A CA 2425368 C CA2425368 C CA 2425368C
- Authority
- CA
- Canada
- Prior art keywords
- denote
- independently
- another
- group
- denotes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LLPGFORTLHNELX-UHFFFAOYSA-N (2-carbamoylphenyl) hydrogen sulfate Chemical class NC(=O)C1=CC=CC=C1OS(O)(=O)=O LLPGFORTLHNELX-UHFFFAOYSA-N 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims description 7
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229910001511 metal iodide Inorganic materials 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 206010001889 Alveolitis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000012895 Gastric disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000001741 anti-phlogistic effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000037902 enteropathy Diseases 0.000 claims description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 208000018556 stomach disease Diseases 0.000 claims description 2
- IYELGEUXPAPULN-UHFFFAOYSA-N 2-hydroxybenzenecarboximidamide Chemical compound NC(=N)C1=CC=CC=C1O IYELGEUXPAPULN-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- ZVJXTEDWOZFOQQ-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1.OC1=CC=CC=C1 ZVJXTEDWOZFOQQ-UHFFFAOYSA-N 0.000 claims 1
- -1 C1-Cg-alkyl groups Chemical group 0.000 description 13
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 150000003937 benzamidines Chemical class 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- VHEYCTCATJSAAI-UHFFFAOYSA-N 4-phenylbenzenecarboximidamide Chemical class C1=CC(C(=N)N)=CC=C1C1=CC=CC=C1 VHEYCTCATJSAAI-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical class NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ZNHVWPKMFKADKW-UHFFFAOYSA-N 12-HETE Chemical compound CCCCCC=CCC(O)C=CC=CCC=CCCCC(O)=O ZNHVWPKMFKADKW-UHFFFAOYSA-N 0.000 description 1
- ZNHVWPKMFKADKW-ZYBDYUKJSA-N 12-HETE Natural products CCCCC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/CCCC(O)=O ZNHVWPKMFKADKW-ZYBDYUKJSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 1
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- INKDAKMSOSCDGL-UHFFFAOYSA-N [O].OC1=CC=CC=C1 Chemical compound [O].OC1=CC=CC=C1 INKDAKMSOSCDGL-UHFFFAOYSA-N 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
- C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The present invention relates to new sulphoxybenzamides of general formula I , processes for preparing them as well as their use as medicaments. (see formula I)
Description
1/1157-ff Boehringer Ingelheim Pharma KG
New sulphoxybenzamides The present invention relates to new sulphoxybenzamides of formula 1, HO O
'S" NR
~ ~ -Z ( A1 Z1 )( AZ Z2 ) NH
" 2 RZ m (I) wherein the groups R1, RZ, R3, A', AZ, Z , Z1, Z2, m and n have the meanings given in the claims and specification, processes for preparing them as well as their use as medicaments, particularly as leukotriene B4 (LTB4) antagonists.
Background to the invention Benzamidine derivatives are known from the prior art as active substances with valuable pharmaceutical properties. Thus, for example, Intern.ational Patent Applications WO
97/21670 and WO 98/11062 disclose inter alia benzamidines which have free hydroxy groups. They contain no references of any kind to benzamidines containing sulphate groups.
The aim of the present invention is to prepare new LTB4 antagonists which, by virtue of their LTB4 antagonistic properties, have many possible uses in the therapeutic field.
Detailed description of the invention Surprisingly, it has been found that benzamidine derivatives containing sulphate groups, of general formula (I) O
O~S" O NR
Q-Z -( AI ZI )m( AZ Z2 )n \ / NH 2 (1) 1/1157-ff Boehringer Ingelheim Pharma KG
New sulphoxybenzamides The present invention relates to new sulphoxybenzamides of formula 1, HO O
'S" NR
~ ~ -Z ( A1 Z1 )( AZ Z2 ) NH
" 2 RZ m (I) wherein the groups R1, RZ, R3, A', AZ, Z , Z1, Z2, m and n have the meanings given in the claims and specification, processes for preparing them as well as their use as medicaments, particularly as leukotriene B4 (LTB4) antagonists.
Background to the invention Benzamidine derivatives are known from the prior art as active substances with valuable pharmaceutical properties. Thus, for example, Intern.ational Patent Applications WO
97/21670 and WO 98/11062 disclose inter alia benzamidines which have free hydroxy groups. They contain no references of any kind to benzamidines containing sulphate groups.
The aim of the present invention is to prepare new LTB4 antagonists which, by virtue of their LTB4 antagonistic properties, have many possible uses in the therapeutic field.
Detailed description of the invention Surprisingly, it has been found that benzamidine derivatives containing sulphate groups, of general formula (I) O
O~S" O NR
Q-Z -( AI ZI )m( AZ Z2 )n \ / NH 2 (1) 1/1157-ff Boehringer Ingelheim Pharma KG
wherein the groups Rl, RZ, R3, A1, A2, Z , Z1, Z2, m and n have the meanings given in the claims and specification, have an LTB4 antagonistic activity and may be used according to the invention for the prevention and treatment of diseases in which LTB4 antagonists may provide a therapeutic benefit.
The invention thus relates to sulphoxybenzamides of general formula I
wherein Z denotes a group selected from the formulae -Xl-(CHZ)r X2- and -CR4R5-, A1 and A 2 independently of one another each denote a 1,4-phenylene- or 1,3-phenylene group optionally substituted by one or more halogen atoms, C1-Cg-alkyl groups, C2-C8-alkenyl groups, C1-C8-haloalkyl groups or C1-C8-alkoxy groups, Z' and Z2 independently of one another each denote a group of formula -X3-(CH2)S X4- or a single bond, R1 denotes hydrogen, hydroxy, -COO-C1-Cg-alkyl or -COO-C1-C4-alkyl-phenyl, whilst in the abovementioned group the phenyl ring in each case may be substituted by CI-C4-alkyl or C1-C4-alkoxy, Rz and R3 independently of one another each denote a hydrogen or halogen atom, or a C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, aryl, aryloxy or aralkyl group, R4 and RS independently of one another each denote hydrogen or C1-C4-alkyl, XI and X2 independently of one another each denote -0, -S, -NH- or a single bond, X3 and X4 independently of one another each denote -0, -S, -NH- or a single bond, m and n independently of one another each denote 0 or 1, and r and s independently of one another denote an integer from 1 to 8, optionally in the form of the tautomers, racemates, enantiomers, diastereomers and mixtures thereof, as well as optionally the pharmacologically acceptable salts thereof.
1/1157-ff Boehringer Ingelheim Pharma KG
The invention thus relates to sulphoxybenzamides of general formula I
wherein Z denotes a group selected from the formulae -Xl-(CHZ)r X2- and -CR4R5-, A1 and A 2 independently of one another each denote a 1,4-phenylene- or 1,3-phenylene group optionally substituted by one or more halogen atoms, C1-Cg-alkyl groups, C2-C8-alkenyl groups, C1-C8-haloalkyl groups or C1-C8-alkoxy groups, Z' and Z2 independently of one another each denote a group of formula -X3-(CH2)S X4- or a single bond, R1 denotes hydrogen, hydroxy, -COO-C1-Cg-alkyl or -COO-C1-C4-alkyl-phenyl, whilst in the abovementioned group the phenyl ring in each case may be substituted by CI-C4-alkyl or C1-C4-alkoxy, Rz and R3 independently of one another each denote a hydrogen or halogen atom, or a C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, aryl, aryloxy or aralkyl group, R4 and RS independently of one another each denote hydrogen or C1-C4-alkyl, XI and X2 independently of one another each denote -0, -S, -NH- or a single bond, X3 and X4 independently of one another each denote -0, -S, -NH- or a single bond, m and n independently of one another each denote 0 or 1, and r and s independently of one another denote an integer from 1 to 8, optionally in the form of the tautomers, racemates, enantiomers, diastereomers and mixtures thereof, as well as optionally the pharmacologically acceptable salts thereof.
1/1157-ff Boehringer Ingelheim Pharma KG
Preferred compounds are those of formula I wherein Z denotes a group selected from the formulae -X1-(CH2)r X2- and -CR4R5-, A' and A2 independently of one another each denote a 1,4-phenylene or 1,3-phenylene group optionally substituted by a C1-C4-alkyl group or C2-C4-alkenyl group, Z' and Z2 independently of one another each denote a group of formula -X3-(CH2)S X4- or a single bond, Rl denotes hydrogen, R2 and R3 each denote a hydrogen atom, R¾ and R5 independently of one another each denote Cl-C4-alkyl, X1 and X2 independently of one another each denote -0- or a single bond, X3 and X4 independently of one another each denote -0- or a single bond, m and n independently of one another each denote 0 or 1, and r and s independently of one another each denote an integer from I to 3.
Another preferred embodiment comprises the compounds of formula I, wherein Z denotes a group of formula -CR4 RS-, 1/1157-ff Boehringer Ingelheim Pharma KG
Another preferred embodiment comprises the compounds of formula I, wherein Z denotes a group of formula -CR4 RS-, 1/1157-ff Boehringer Ingelheim Pharma KG
AI and A 2 independently of one another each denote a 1,4-phenylene or 1,3-phenylene group optionally substituted by a C1-C4-alkyl group or C2-C4-alkenyl group, and preferably A' denotes 1,4-phenylene and A2 denotes 1,3-phenylene, Z1 and Z2 independently of one another each denote a group of formula -X3-(CH2)s-X4-, and preferably Z1 denotes -O-CH2- and Z2 denotes -CH2-O-R' denotes hydrogen, R2 and R3 each denote a hydrogen atom, R4 and R5 each denote methyl, X3 and X4 independently of one another each denote -0- or a single bond, m and n each denote 1, and s denotes 1.
Also preferred are compounds of formula I wherein Z denotes a group of formula -Xl-(CH2)r X2-, A 2 denotes a 1,4-phenylene group substituted by a C1-C4-alkyl group or C2-C4-alkenyl group, preferably a 1,4-phenylene group substituted by an n-propyl or allyl group, Z2 denotes a single bond, R' denotes hydrogen, R2 and R3 each denote a hydrogen atom, Xt and X2 independently of one another each denote -0-, 1/1157-ff Boehringer Ingelheim Pharma KG
m denotes 0, n denotes 1, and r denotes 2.
Unless specifically stated otherwise, the general definitions are used in the following sense:
Ci-Cg-alkyl and C1-C4-alkyl generally denote a branched or unbranched hydrocarbon group with 1 to 4 or 8 carbon atom(s), which may optionally be substituted by one or more halogen atom(s), preferably fluorine, which may be identical to or different from one another. The following hydrocarbon groups are mentioned as examples:
methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-l-methylpropyl and 1-ethyl-2-methylpropyl. Unless otherwise stated, lower alkyl groups with 1 to 4 carbon atoms are preferred, such as methyl; ethyl, n-propyl, iso-propyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl.
C2-C8-alkenyl and C2-C4-alkenyl generally denote a branched or unbranched unsaturated hydrocarbon group with 2 to 4 or 8 carbon atom(s), which may optionally be substituted by one or more halogen atom(s), preferably fluorine, which may be identical to or different from one another. The following hydrocarbon groups are mentioned as examples:
Vinyl, allyl, prop-1-enyl, butenyl, pentenyl, hexenyl, heptenyl and octenyl.
Unless otherwise stated, lower alkenyl groups with 2 to 4 carbon atoms, such as vinyl or allyl, are preferred.
1/1157-ff Boehringer Ingelheim Pharma KG
Also preferred are compounds of formula I wherein Z denotes a group of formula -Xl-(CH2)r X2-, A 2 denotes a 1,4-phenylene group substituted by a C1-C4-alkyl group or C2-C4-alkenyl group, preferably a 1,4-phenylene group substituted by an n-propyl or allyl group, Z2 denotes a single bond, R' denotes hydrogen, R2 and R3 each denote a hydrogen atom, Xt and X2 independently of one another each denote -0-, 1/1157-ff Boehringer Ingelheim Pharma KG
m denotes 0, n denotes 1, and r denotes 2.
Unless specifically stated otherwise, the general definitions are used in the following sense:
Ci-Cg-alkyl and C1-C4-alkyl generally denote a branched or unbranched hydrocarbon group with 1 to 4 or 8 carbon atom(s), which may optionally be substituted by one or more halogen atom(s), preferably fluorine, which may be identical to or different from one another. The following hydrocarbon groups are mentioned as examples:
methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-l-methylpropyl and 1-ethyl-2-methylpropyl. Unless otherwise stated, lower alkyl groups with 1 to 4 carbon atoms are preferred, such as methyl; ethyl, n-propyl, iso-propyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl.
C2-C8-alkenyl and C2-C4-alkenyl generally denote a branched or unbranched unsaturated hydrocarbon group with 2 to 4 or 8 carbon atom(s), which may optionally be substituted by one or more halogen atom(s), preferably fluorine, which may be identical to or different from one another. The following hydrocarbon groups are mentioned as examples:
Vinyl, allyl, prop-1-enyl, butenyl, pentenyl, hexenyl, heptenyl and octenyl.
Unless otherwise stated, lower alkenyl groups with 2 to 4 carbon atoms, such as vinyl or allyl, are preferred.
1/1157-ff Boehringer Ingelheim Pharma KG
The group -(CH2)r or -(CH2)S- denotes a branched or unbranched double-bonded hydrocarbon bridge with 1 to 8 carbon atoms, which may optionally be substituted by one or more halogen atom(s), preferably fluorine, which may be identical to or different from one another.
Aryl generally denotes an aromatic group with 6 to 10 carbon atoms, preferably phenyl, while the aromatic group may be substituted by one or more lower alkyl group(s), lower alkenyl group(s), trifluoromethyl group(s), cyano group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s), which may be identical or different; the preferred aryl group is an optionally substituted phenyl group, the preferred substituents being halogen - such as fluorine, chlorine or bromine - as well as hydroxyl.
Alkoxy generally denotes a straight-chain or branched hydrocarbon group with 1 to 8 carbon atom(s) bound via an oxygen atom. A lower alkoxy group with 1 to 3 carbon atom(s) is preferred. The methoxy group is particularly preferred.
Aryloxy generally denotes an aromatic group with 6 to 10 carbon atoms bound via an oxygen, preferably phenoxy, whilst the aromatic group may be substituted by one or more lower alkyl group(s), lower alkenyl group(s), trifluoromethyl group(s), cyano group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s), which may be identical or different; the preferred aryl group is an optionally substituted phenyl group, the preferred substituents being halogen - such as fluorine, chlorine or bromine - as well as hydroxyl.
Aralkyl generally denotes a aromatic group with 6 to 10 carbon atoms bound via an alkylene group, preferably phenylalkyl, whilst the aromatic group may be substituted by one or more lower alkyl group(s), lower alkenyl group(s), trifluoromethyl group(s), cyano group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s), which may be identical or different; the preferred aryl group is an optionally substituted phenyl group, the preferred substituents being halogen - such as fluorine, chlorine or bromine -as well as hydroxyl. The alkylene group is generally a double-bonded hydrocarbon bridge with 1 to 8 carbon atoms, preferably 1 to 3 carbon atoms, optionally substituted by one or more halogen atom(s) - preferably fluorine - which may be identical to or different from one another.
1/1157-ff Boehringer Ingelheim Pharma KG
Aryl generally denotes an aromatic group with 6 to 10 carbon atoms, preferably phenyl, while the aromatic group may be substituted by one or more lower alkyl group(s), lower alkenyl group(s), trifluoromethyl group(s), cyano group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s), which may be identical or different; the preferred aryl group is an optionally substituted phenyl group, the preferred substituents being halogen - such as fluorine, chlorine or bromine - as well as hydroxyl.
Alkoxy generally denotes a straight-chain or branched hydrocarbon group with 1 to 8 carbon atom(s) bound via an oxygen atom. A lower alkoxy group with 1 to 3 carbon atom(s) is preferred. The methoxy group is particularly preferred.
Aryloxy generally denotes an aromatic group with 6 to 10 carbon atoms bound via an oxygen, preferably phenoxy, whilst the aromatic group may be substituted by one or more lower alkyl group(s), lower alkenyl group(s), trifluoromethyl group(s), cyano group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s), which may be identical or different; the preferred aryl group is an optionally substituted phenyl group, the preferred substituents being halogen - such as fluorine, chlorine or bromine - as well as hydroxyl.
Aralkyl generally denotes a aromatic group with 6 to 10 carbon atoms bound via an alkylene group, preferably phenylalkyl, whilst the aromatic group may be substituted by one or more lower alkyl group(s), lower alkenyl group(s), trifluoromethyl group(s), cyano group(s), alkoxy group(s), nitro group(s), amino group(s) and/or one or more halogen atom(s), which may be identical or different; the preferred aryl group is an optionally substituted phenyl group, the preferred substituents being halogen - such as fluorine, chlorine or bromine -as well as hydroxyl. The alkylene group is generally a double-bonded hydrocarbon bridge with 1 to 8 carbon atoms, preferably 1 to 3 carbon atoms, optionally substituted by one or more halogen atom(s) - preferably fluorine - which may be identical to or different from one another.
1/1157-ff Boehringer Ingelheim Pharma KG
Most particularly preferred compounds are those of formulae IA and IB, NH
HO NH z O S
O / O~~O
\ I
~IA) \
z HO--O, \ I \ I I/ NH
O O O O
(IB) The compounds IA and IB may be formed in vivo as metabolites of a corresponding LTB4-antagonistic compound with a free hydroxy group and exhibit the following Ki values in the receptor binding test:
Compound Ki [nM]
IA 3.2 IB 40.0 As has been found, the compounds of formula I are characterised by their versatility of use in the therapeutic field. Particular emphasis should be laid on those applications for which the LTB4-receptor-antagonistic properties play a part.
The following should be mentioned in particular: arthritis, asthma, chronic obstructive lung diseases such as chronic bronchitis, psoriasis, ulcerative colitis, gastro- or enteropathy induced by nonsteroidal antiphlogistics, cystic or pulmonary fibrosis, Alzheimer`s disease, shock, reperfusion damage/ischaemia such as stroke or cardiac infarct, atherosclerosis, multiple sclerosis, autoimmune diseases, malignant neoplasia, alveolitis.
1/1157-ff Boehringer Ingelheim Pharma KG
HO NH z O S
O / O~~O
\ I
~IA) \
z HO--O, \ I \ I I/ NH
O O O O
(IB) The compounds IA and IB may be formed in vivo as metabolites of a corresponding LTB4-antagonistic compound with a free hydroxy group and exhibit the following Ki values in the receptor binding test:
Compound Ki [nM]
IA 3.2 IB 40.0 As has been found, the compounds of formula I are characterised by their versatility of use in the therapeutic field. Particular emphasis should be laid on those applications for which the LTB4-receptor-antagonistic properties play a part.
The following should be mentioned in particular: arthritis, asthma, chronic obstructive lung diseases such as chronic bronchitis, psoriasis, ulcerative colitis, gastro- or enteropathy induced by nonsteroidal antiphlogistics, cystic or pulmonary fibrosis, Alzheimer`s disease, shock, reperfusion damage/ischaemia such as stroke or cardiac infarct, atherosclerosis, multiple sclerosis, autoimmune diseases, malignant neoplasia, alveolitis.
1/1157-ff Boehringer Ingelheim Pharma KG
The new compounds may also be used to treat illnesses or conditions in which the passage of cells from the blood through the vascular endothelium into the tissues is of importance (such as metastasis) or illnesses and conditions in which the combination of LTB4 or another active substance (such as 12-HETE) with the LTB4 receptor has an influence on cell proliferation (e.g. chronic myeloid leukaemia).
The new compound may also be used in conjunction with other active substances, e.g. those which are used for the same indications, or e.g. with antiallergic agents, secretolytics,132-adrenergics, steroids taken by inhalation, antihistamines, PDE4 inhibitors, peptido-leukotriene antagonists and/or PAF antagonists. They may be administered topically, orally, transdermally, nasally, parenterally or by inhalation.
The activity can be investigated pharmacologically and biochemically using tests as disclosed for example in WO 93/16036, pp. 15 to 17; reference is hereby made to the contents of this publication.
The therapeutic or prophylactic dose depends - apart from the potency of the individual compounds and the patient's body weight - on the nature and gravity of the condition. For oral administration the dosage is between 10 and 500 mg, preferably between 20 and 250 mg.
By inhalation the amount of active substance delivered to the patient is between about 0.5 and 25, preferably between about 2 and 20 mg.
Solutions for inhalation generally contain between about 0.5 and 5 % of active substance. The new compounds may be administered in conventional preparations, e.g. as plain or coated tablets, capsules, lozenges, powders, granules, solutions, emulsions, syrups, aerosols for inhalation, ointments and suppositories.
The following Examples show some possible ways of formulating the preparations:
1/1157-ff Boehringer Ingelheim Pharma KG
The new compound may also be used in conjunction with other active substances, e.g. those which are used for the same indications, or e.g. with antiallergic agents, secretolytics,132-adrenergics, steroids taken by inhalation, antihistamines, PDE4 inhibitors, peptido-leukotriene antagonists and/or PAF antagonists. They may be administered topically, orally, transdermally, nasally, parenterally or by inhalation.
The activity can be investigated pharmacologically and biochemically using tests as disclosed for example in WO 93/16036, pp. 15 to 17; reference is hereby made to the contents of this publication.
The therapeutic or prophylactic dose depends - apart from the potency of the individual compounds and the patient's body weight - on the nature and gravity of the condition. For oral administration the dosage is between 10 and 500 mg, preferably between 20 and 250 mg.
By inhalation the amount of active substance delivered to the patient is between about 0.5 and 25, preferably between about 2 and 20 mg.
Solutions for inhalation generally contain between about 0.5 and 5 % of active substance. The new compounds may be administered in conventional preparations, e.g. as plain or coated tablets, capsules, lozenges, powders, granules, solutions, emulsions, syrups, aerosols for inhalation, ointments and suppositories.
The following Examples show some possible ways of formulating the preparations:
1/1157-ff Boehringer Ingelheim Pharma KG
Examples of formulations 1. Tablets Composition:
Active substance according to the invention 20 parts by weight Stearic acid 6 parts by weight Glucose 474 parts by weight The ingredients are processed in the usual way to form tablets weighing 500 mg. If desired, the active substance content may be increased or reduced and the quantity of glucose reduced or increased accordingly.
2. Suppositories Composition:
Active substance according to the invention 100 parts by weight Powdered lactose 45 parts by weight Cocoa butter 1555 parts by weight The ingredients are processed in the usual way to form suppositories weighing 1.7 g.
3. Powder for inhalation Micronised powdered active substance (compound of formula I; particle size about 0.5 to 7 m) is packed into hard gelatine capsules in quantities of 5 mg, optionally with the addition of micronised lactose. The powder is inhaled from conventional inhalers, e.g.
according to DE-A
33 45 722, to which reference is hereby made.
The compounds according to the invention compound are prepared using methods known per se from the prior art. Thus, the compounds of general formula I may be prepared by reacting the benzamides of formula II which contain hydroxy groups:
1/1157-ff Boehringer Ingelheim Pharma KG
NR' OH
Z (A1 Z1 )m( AZ Z2 NH Jn \ / 2 (II) which are known, for example, from International Patent Applications WO
97/21670 and WO
98/11062, wherein Z , A1, A2, Z1, Z2 , Rl, R2, R3, m and n are as hereinbefore defined, with a sulphuric acid derivative of formula III, 5 HO3S-X ( III ) wherein X denotes a leaving group which may be substituted by a phenol oxygen, preferably a halogen atom, particularly chlorine, preferably in the presence of a weak base and a metal iodide.
Active substance according to the invention 20 parts by weight Stearic acid 6 parts by weight Glucose 474 parts by weight The ingredients are processed in the usual way to form tablets weighing 500 mg. If desired, the active substance content may be increased or reduced and the quantity of glucose reduced or increased accordingly.
2. Suppositories Composition:
Active substance according to the invention 100 parts by weight Powdered lactose 45 parts by weight Cocoa butter 1555 parts by weight The ingredients are processed in the usual way to form suppositories weighing 1.7 g.
3. Powder for inhalation Micronised powdered active substance (compound of formula I; particle size about 0.5 to 7 m) is packed into hard gelatine capsules in quantities of 5 mg, optionally with the addition of micronised lactose. The powder is inhaled from conventional inhalers, e.g.
according to DE-A
33 45 722, to which reference is hereby made.
The compounds according to the invention compound are prepared using methods known per se from the prior art. Thus, the compounds of general formula I may be prepared by reacting the benzamides of formula II which contain hydroxy groups:
1/1157-ff Boehringer Ingelheim Pharma KG
NR' OH
Z (A1 Z1 )m( AZ Z2 NH Jn \ / 2 (II) which are known, for example, from International Patent Applications WO
97/21670 and WO
98/11062, wherein Z , A1, A2, Z1, Z2 , Rl, R2, R3, m and n are as hereinbefore defined, with a sulphuric acid derivative of formula III, 5 HO3S-X ( III ) wherein X denotes a leaving group which may be substituted by a phenol oxygen, preferably a halogen atom, particularly chlorine, preferably in the presence of a weak base and a metal iodide.
10 In a preferred embodiment of the process according to the invention a compound of formula II
or an acid addition salt thereof is reacted with a sulphuric acid derivative of formula III, particularly chlorosulphonic acid, in an inert diluent and in the presence of a base, or in a basic solvent such as, for example, triethylamine or pyridine, and in the presence of catalytic amounts of a metal iodide, preferably an alkali metal iodide, particularly potassium iodide, at a temperature of from - 80 to + 120 C, preferably from -40 to +100 C, particularly from -10 to + 80 C. Under these preferred conditions the reaction is generally complete in 2 to 36 hours, preferably 4 to 18 hours.
The compound according to the invention may be prepared, starting from compounds known from the prior art, using the processes described in the following Examples, inter alia.
Various other embodiments of the process will be apparent to anyone skilled in the art from the present specification. It is specifically pointed out, however, that these Examples and the related description are provided solely as an illustration and are not to be regarded as restricting the invention.
1/1157-ff Boehringer Ingelheim Pharma KG
or an acid addition salt thereof is reacted with a sulphuric acid derivative of formula III, particularly chlorosulphonic acid, in an inert diluent and in the presence of a base, or in a basic solvent such as, for example, triethylamine or pyridine, and in the presence of catalytic amounts of a metal iodide, preferably an alkali metal iodide, particularly potassium iodide, at a temperature of from - 80 to + 120 C, preferably from -40 to +100 C, particularly from -10 to + 80 C. Under these preferred conditions the reaction is generally complete in 2 to 36 hours, preferably 4 to 18 hours.
The compound according to the invention may be prepared, starting from compounds known from the prior art, using the processes described in the following Examples, inter alia.
Various other embodiments of the process will be apparent to anyone skilled in the art from the present specification. It is specifically pointed out, however, that these Examples and the related description are provided solely as an illustration and are not to be regarded as restricting the invention.
1/1157-ff Boehringer Ingelheim Pharma KG
Example 1 Benzenecarboximidamides, 4-[[3-[[4-[1-methyl-l-[4-(sulphoxy)phenyl] ethyl]phenoxy]methyl]phenyl]methoxy] -0 ~ \ NH2 HO---SO O O ~
O
7.54 g of benzenecarboximidamides, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy], monohydrochloride were taken up in 200 ml of pyridine and combined with 4.0 g of chlorosulphonic acid (slowly added at ambient temperature) as well as a trace of potassium iodide. The mixture was stirred for 6 h at 60 C.
1 o Then the reaction mixture was carefully added to water, the precipitate was suction filtered and washed with methanol. Yield: 4.0 g (m.p. 284 C).
Example 2 [1,1'-Biphenyl]-4-carboximidamides, 3'-propyl-4'-[2-[3-(sulphoxy)phenoxy]ethoxy]-NH
HO
O~S/
2.43 g of [1,1'-Biphenyl]-4-carboximidamides, 4'-[2-(3-hydroxyphenoxy)ethoxy]-3'-propyl, monomethanesulphonate, 100 ml of pyridine and 0.1 g of potassium iodide were combined and 1.5 g of chlorosulphonic acid were slowly added dropwise with stirring.
The mixture was stirred for 6 hours at 50-60 C. After cooling the mixture was added to 1 litre of water, the crystals precipitated were suction filtered and recrystallised 2x from dimethylformamide.
1.25 g of white crystals. M.p. > 270 C:
1/1157-ff Boehringer Ingelheim Pharma KG
O
7.54 g of benzenecarboximidamides, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methylethyl]phenoxy]methyl]phenyl]methoxy], monohydrochloride were taken up in 200 ml of pyridine and combined with 4.0 g of chlorosulphonic acid (slowly added at ambient temperature) as well as a trace of potassium iodide. The mixture was stirred for 6 h at 60 C.
1 o Then the reaction mixture was carefully added to water, the precipitate was suction filtered and washed with methanol. Yield: 4.0 g (m.p. 284 C).
Example 2 [1,1'-Biphenyl]-4-carboximidamides, 3'-propyl-4'-[2-[3-(sulphoxy)phenoxy]ethoxy]-NH
HO
O~S/
2.43 g of [1,1'-Biphenyl]-4-carboximidamides, 4'-[2-(3-hydroxyphenoxy)ethoxy]-3'-propyl, monomethanesulphonate, 100 ml of pyridine and 0.1 g of potassium iodide were combined and 1.5 g of chlorosulphonic acid were slowly added dropwise with stirring.
The mixture was stirred for 6 hours at 50-60 C. After cooling the mixture was added to 1 litre of water, the crystals precipitated were suction filtered and recrystallised 2x from dimethylformamide.
1.25 g of white crystals. M.p. > 270 C:
1/1157-ff Boehringer Ingelheim Pharma KG
Examples 3-14 The following compounds NH
:o0 Z
are prepared analogously to Examples 1 and 2 from the corresponding phenols:
Example No. X R 2 R
3 4-HO3SO- H n-C3H7 4 4-HO3SO-phenyl H n-C3H7 5 4-HO3SO- 3-phenyl n-C3H7 6 4-HO3SO- 2-n-C3H7 n-C3H7 7 4-(4-HO3SO-phenoxy)- H n-C3H7 8 4-[1-(4-HO3SO-phenyl)-1-methyl]-ethyl H n-C3H7 9 4-[1-(4-HO3SO-phenyl)-1-methyl]-ethyl 2-n-C3H7 n-C3H7 3-HO3SO- 2-n-C3H7 n-C3H7 11 2-HO3SO- H n-C3H7 12 5-HO3SO- 2-n-C3H7 n-C3H7 13 3-HO3SO- 4-CH3-O- n-C3H7 14 3-HO3SO- H CH2=CH-CH2-
:o0 Z
are prepared analogously to Examples 1 and 2 from the corresponding phenols:
Example No. X R 2 R
3 4-HO3SO- H n-C3H7 4 4-HO3SO-phenyl H n-C3H7 5 4-HO3SO- 3-phenyl n-C3H7 6 4-HO3SO- 2-n-C3H7 n-C3H7 7 4-(4-HO3SO-phenoxy)- H n-C3H7 8 4-[1-(4-HO3SO-phenyl)-1-methyl]-ethyl H n-C3H7 9 4-[1-(4-HO3SO-phenyl)-1-methyl]-ethyl 2-n-C3H7 n-C3H7 3-HO3SO- 2-n-C3H7 n-C3H7 11 2-HO3SO- H n-C3H7 12 5-HO3SO- 2-n-C3H7 n-C3H7 13 3-HO3SO- 4-CH3-O- n-C3H7 14 3-HO3SO- H CH2=CH-CH2-
Claims (14)
1. New sulphoxybenzamides of general formula I
wherein Z0 denotes a group selected from the formulae -X1-(CH2)r-X2- and -CR4R5-, A1 and A2 independently of one another each denote a 1,4-phenylene- or 1,3-phenylene group optionally substituted by one or more halogen atoms, C1-C8-alkyl groups, C2-C8-alkenyl groups, C1-C8-haloalkyl groups or C1-C8-alkoxy groups, Z1 and Z2 independently of one another each denote a group of formula -X3-(CH2)s-X4- or a single bond, R1 denotes hydrogen, hydroxy, -COO-C1-C8-alkyl or -COO-C1-C4-alkyl-phenyl, whilst in the abovementioned group the phenyl ring in each case may be substituted by C1-C4-alkyl or C1-C4-alkoxy, R2 and R3 independently of one another each denote a hydrogen or halogen atom, or a C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, aryl, aryloxy or aralkyl group, R4 and R5 independently of one another each denote hydrogen or C1-C4-alkyl, X1 and X2 independently of one another each denote -O, -S, -NH- or a single bond, X3 and X4 independently of one another each denote -O, -S, -NH- or a single bond, m and n independently of one another each denote 0 or 1, and r and s independently of one another each denote an integer from 1 to 8, optionally in the form of the tautomers, racemates, enantiomers, diastereomers and mixtures thereof, as well as optionally the pharmacologically acceptable salts thereof.
wherein Z0 denotes a group selected from the formulae -X1-(CH2)r-X2- and -CR4R5-, A1 and A2 independently of one another each denote a 1,4-phenylene- or 1,3-phenylene group optionally substituted by one or more halogen atoms, C1-C8-alkyl groups, C2-C8-alkenyl groups, C1-C8-haloalkyl groups or C1-C8-alkoxy groups, Z1 and Z2 independently of one another each denote a group of formula -X3-(CH2)s-X4- or a single bond, R1 denotes hydrogen, hydroxy, -COO-C1-C8-alkyl or -COO-C1-C4-alkyl-phenyl, whilst in the abovementioned group the phenyl ring in each case may be substituted by C1-C4-alkyl or C1-C4-alkoxy, R2 and R3 independently of one another each denote a hydrogen or halogen atom, or a C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, aryl, aryloxy or aralkyl group, R4 and R5 independently of one another each denote hydrogen or C1-C4-alkyl, X1 and X2 independently of one another each denote -O, -S, -NH- or a single bond, X3 and X4 independently of one another each denote -O, -S, -NH- or a single bond, m and n independently of one another each denote 0 or 1, and r and s independently of one another each denote an integer from 1 to 8, optionally in the form of the tautomers, racemates, enantiomers, diastereomers and mixtures thereof, as well as optionally the pharmacologically acceptable salts thereof.
2. Compounds of formula I according to claim 1, wherein Z0 denotes a group selected from the formulae -X1-(CH2)r-X2- and -CR4R5-, A1 and A2 independently of one another each denote a 1,4-phenylene or 1,3-phenylene group optionally substituted by a C1-C4-alkyl group or C2-C4-alkenyl group, Z1 and Z2 independently of one another each denote a group of formula -X3-(CH2)s-X4- or a single bond, R1 denotes hydrogen, R2 and R3 each denote a hydrogen atom, R4 and R5 independently of one another each denote C1-C4-alkyl, X1 and X2 independently of one another each denote -O- or a single bond, X3 and X4 independently of one another each denote -O- or a single bond, m and n independently of one another each denote 0 or 1, and r and s independently of one another each denote an integer from 1 to 3.
3. Compounds of formula I according to claim 1 or 2, wherein Z0 denotes a group of formula -X1-(CH2)r-X2-, A 2 denotes a 1,4-phenylene group substituted by a C1-C4-alkyl or C2-C4-alkenyl group, Z2 denotes a single bond, R1 denotes hydrogen, R2 and R3 each denote a hydrogen atom, X1 and X2 independently of one another each denote -O-, m denotes 0, n denotes 1, and r denotes 2.
4. Compound of formula IA
5. Compounds of formula I according to claim 1 or 2, wherein Z0 denotes a group of formula -CR4R5-, A1 and A2 independently of one another each denote a 1,4-phenylene or 1,3-phenylene group optionally substituted by a C1-C4-alkyl group, Z1 and Z2 independently of one another each denote a group of formula -X3-(CH2)s-X4-, R denotes hydrogen, R2 and R3 each denote a hydrogen atom, R4 and R5 each denote methyl, X3 and X4 independently of one another each denote -O- or a single bond, m and n each denote 1, and s denotes 1.
6. Compound of formula IB
7. Compounds of formulae I, IA or IB according to one of claims 1 to 6 for use as pharmaceutical compositions.
8. Process for preparing compounds of formulae I, IA or IB according to one of claims 1 to 6, characterised in that a hydroxybenzamidine of formula II
wherein Z0, A1, A2, Z1, Z2, R1, R2, R3, m and n have the meanings given in claims 1 to 6, is reacted with a sulphuric acid derivative of formula III, HO3S-X ( III ) wherein X denotes a leaving group which can be substituted by a phenoxide oxygen.
wherein Z0, A1, A2, Z1, Z2, R1, R2, R3, m and n have the meanings given in claims 1 to 6, is reacted with a sulphuric acid derivative of formula III, HO3S-X ( III ) wherein X denotes a leaving group which can be substituted by a phenoxide oxygen.
9. Process according to claim 7, characterised in that the reaction is carried out in the presence of a weak base and a metal iodide.
10. Pharmaceutical preparation containing a compound according to one of claims 1 to 6 and pharmaceutically acceptable carriers and excipients.
11. Use of compounds according to one of claims 1 to 6 for preparing a medicament.
12. Use of compounds according to claim 10 for preparing a medicament with an antagonistic activity.
13. Use of compounds of general formula I according to one of claims 1 to 6, the stereoisomers thereof as well as the acid addition salts thereof for preparing a medicament for the therapeutic treatment of arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, ulcerative colitis, gastro- or enteropathy induced by nonsteroidal antiphlogistics, cystic or pulmonary fibrosis, Alzheimer's disease, shock, reperfusion damage/ischaemia, atherosclerosis, multiple sclerosis, autoimmune diseases, malignant neoplasia, alveolitis.
14. Method of treating and/or preventing diseases in which LTB4-antagonists develop a therapeutic benefit, by administering a therapeutically effective amount of one or more compounds of general formula I according to one of claims 1 to 6, the stereoisomers thereof or the acid addition salts thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10052333.1 | 2000-10-24 | ||
| DE10052333A DE10052333A1 (en) | 2000-10-24 | 2000-10-24 | New sulfooxybenzamides |
| PCT/EP2001/012127 WO2002034715A1 (en) | 2000-10-24 | 2001-10-19 | Benzamidine derivatives comprising a sulfate group serving as ltb4 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2425368A1 CA2425368A1 (en) | 2003-04-08 |
| CA2425368C true CA2425368C (en) | 2008-12-09 |
Family
ID=7660637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002425368A Expired - Fee Related CA2425368C (en) | 2000-10-24 | 2001-10-19 | New sulphoxybenzamides |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1332128A1 (en) |
| JP (1) | JP3917516B2 (en) |
| AU (1) | AU2002210558A1 (en) |
| CA (1) | CA2425368C (en) |
| DE (1) | DE10052333A1 (en) |
| MX (1) | MXPA03003465A (en) |
| PE (1) | PE20020542A1 (en) |
| WO (1) | WO2002034715A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262223B2 (en) | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
| EP1997491B1 (en) * | 2004-07-14 | 2010-09-22 | Inflammation Research Center Company Ltd. | Method for inhibiting tumor metastasis |
| EP1792623B1 (en) * | 2005-07-08 | 2010-03-10 | Leopold-Franzens-Universität Innsbruck | Use of extracts and constituents of leontopodium as enhancers of cholinergic function |
| CN100402494C (en) * | 2005-08-25 | 2008-07-16 | 江苏吴中苏药医药开发有限责任公司 | Myoinositol sulfate aluminium , its preparation method and oral compositions and uses |
| WO2012122969A1 (en) | 2011-03-16 | 2012-09-20 | Creative Therapeutics Gmbh | Substituted diphenyl derivatives |
| CA3063334A1 (en) | 2017-05-12 | 2019-12-05 | Riken | Modified class a gpcr binding compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA43318C2 (en) * | 1992-02-05 | 2001-12-17 | Берінгер Інгельхейм Кг | Amidine derivatives, pharmaceutical composition with ltb-4 antagonistic effect |
| DE19546452A1 (en) * | 1995-12-13 | 1997-06-19 | Boehringer Ingelheim Kg | New phenylamidine derivatives, process for their preparation and their use as medicaments |
| DE19636689A1 (en) * | 1996-09-10 | 1998-03-12 | Boehringer Ingelheim Kg | New benzamidine derivatives |
-
2000
- 2000-10-24 DE DE10052333A patent/DE10052333A1/en not_active Withdrawn
-
2001
- 2001-10-19 WO PCT/EP2001/012127 patent/WO2002034715A1/en not_active Ceased
- 2001-10-19 MX MXPA03003465A patent/MXPA03003465A/en unknown
- 2001-10-19 JP JP2002537708A patent/JP3917516B2/en not_active Expired - Fee Related
- 2001-10-19 AU AU2002210558A patent/AU2002210558A1/en not_active Abandoned
- 2001-10-19 EP EP01978439A patent/EP1332128A1/en not_active Withdrawn
- 2001-10-19 CA CA002425368A patent/CA2425368C/en not_active Expired - Fee Related
- 2001-10-22 PE PE2001001045A patent/PE20020542A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002210558A1 (en) | 2002-05-06 |
| MXPA03003465A (en) | 2004-12-06 |
| PE20020542A1 (en) | 2002-07-16 |
| DE10052333A1 (en) | 2002-05-02 |
| WO2002034715A1 (en) | 2002-05-02 |
| JP2004512322A (en) | 2004-04-22 |
| CA2425368A1 (en) | 2003-04-08 |
| JP3917516B2 (en) | 2007-05-23 |
| EP1332128A1 (en) | 2003-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4288299B2 (en) | Benzamidine derivatives having LTB4-antagonist activity and their use as pharmaceuticals | |
| US7659293B2 (en) | α-Amino-N-hydroxy-acetamide derivatives | |
| JP2002322143A (en) | Amidine derivatives, their preparation, and pharmaceutical compositions | |
| KR100293867B1 (en) | Aminosteelbazole Derivatives and Medicines | |
| HU224823B1 (en) | Substituted benzamidines,process for preparing the said compds. and pharmaceutical compns. contg. them | |
| US7141595B2 (en) | Amino benzothiazole compounds with NOS inhibitory activity | |
| JPH03505728A (en) | Synthetic methods and new pharmaceutical compounds | |
| US5686496A (en) | Chemical compound, the preparation thereof and its use in pharmaceutical compositions | |
| IE841873L (en) | Quinoline carboxylic acids and derivatives | |
| US6335338B1 (en) | Calcilytic compounds | |
| CA2425368C (en) | New sulphoxybenzamides | |
| EP0306827B1 (en) | Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same | |
| US20250074904A1 (en) | Nsd2-targeted checmical degraderts and compositions and methods of use thereof | |
| EP0228959A2 (en) | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | |
| US4413011A (en) | Substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides as anti-arteriosclerotic agents and method | |
| US6489359B2 (en) | Sulphoxybenzamides | |
| US6291459B1 (en) | Calcilytic compounds | |
| US6291531B1 (en) | LTB4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition | |
| US4882357A (en) | Novel N-(substituted-phenyl)-5-(substituted-2,5-dimethylphenoxy)-2,2-dimethylpentanamides | |
| US8871764B2 (en) | Lisofylline analogs and methods for use | |
| EP0335408A2 (en) | Substituted benzene derivatives, processes for their production and antitumour compositions containing them | |
| US20060167003A1 (en) | Probucol derivatives | |
| US5326870A (en) | Substituted sulfonamide derivative and a pharmaceutical composition comprising the same | |
| US4554282A (en) | Substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides as anti-arteriosclerotic agents and method | |
| JPS6270335A (en) | Bicyclic allyl ether derivatives, their production methods and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |